Kailera Q2 net loss widens to $111.3 million as R&D spending rises sharply
Kailera Therapeutics reported a second-quarter 2026 net loss of $111.3 million, up from $28.9 million a year earlier, as research and development expenses rose to $101.1 million from $19.5 million. The company had $1,171.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects to fund operations into mid-2028. For shareholders, the filing shows a much larger loss driven by expanded clinical development, and the statement of operations reports no revenue.
Key points
- Q2 2026 net loss was $111.3 million, compared with $28.9 million in Q2 2025.
- R&D expenses were $101.1 million versus $19.5 million; G&A expenses were $20.3 million versus $11.1 million.
- Cash, cash equivalents and marketable securities totaled $1,171.8 million as of June 30, 2026, with runway into mid-2028.
- Ribupatide oral has an active U.S. FDA IND; global Phase 3 obesity trial initiation is planned for the first half of 2027.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.